|
|
|
Why America's medicine became a national security question
|
|
by American Biosecurity Initiative
|
Beijing spent twenty years treating biotechnology as strategic infrastructure while Washington debated it as health spending. Reclaiming the lead means building American strength at home and extending it through allies. Five years ago, American pharmaceutical companies licensed almost none of their new drug candidates from
China, and today the share is close to a third. A July 2026 literature review by Start Grow Remain assembles the public record behind that number, tracing how a country that spent two decades supplying the ingredients in America's generic medicines became a source of the innovation behind new therapies. The record points to a conclusion Washington has been slow to reach, which is that the surest protection is a stronger America. The story starts with the basics. Roughly nine in ten active ingredients in
American generic drugs originate abroad, and hospital staff now spend some 20 million hours a year managing shortages of antibiotics, sedatives, and chemotherapy agents, more than double the burden of 2019. That is an industrial problem with an industrial fix, and it has held Washington's attention for a decade. What Washington has watched less closely is the more consequential change unfolding upstream, in the discovery of new medicines. | | China moved to the frontier | Chinese clinical trial volume reached roughly 120 percent of the U.S. level in 2024, and the Information Technology and Innovation Foundation concludes that China has already passed the United States as the site for certain categories of clinical development. The volume matters because trials are how a research
system learns; a country that runs more of them, faster, learns more each year. Chinese institutions now work at the frontier of synthetic biology, genomic sequencing, and machine-assisted discovery, leveraging biomedical datasets of unparalleled scale alongside computing resources concentrated on advancing these fields. The National Security Commission on Emerging Biotechnology, a bipartisan federal body, stated the consequence plainly in 2025: under
current investment trends, the United States will field the biotechnology of the last decade while a competitor fields the next. The commission concluded that the country had roughly three years to act, and it has since cautioned that the window is closing faster than expected. | | Beijing organized for this | None of this happened by accident. China's Five-Year Plan names biomanufacturing and reduced foreign dependence as explicit priorities, and government procurement steers the domestic market toward Chinese firms. Over the past two decades, Beijing has concentrated universities, hospitals, startups, and contract research organizations into clusters built to move discoveries from lab to market, recruiting talent from the United States and its allies along the way.
Biotechnology now sits in Beijing's planning documents alongside semiconductors and artificial intelligence, and it is resourced accordingly. Chinese leaders concluded years ago that biotechnology was a national security asset, and they organized a generation of policy around becoming its global leader. | | The conditions at home | While Beijing was organizing, the American discovery base was quietly thinning. Discovery capacity is expensive to build, slow to rebuild, and rarely announces its own decline. American biopharmaceutical venture funding fell by roughly 20 percent in early 2025, according to one count by the Center for Strategic and International Studies, which means fewer companies forming
around promising science and fewer bets on the therapies of the next decade. The workforce is moving in the same direction. Nearly a fifth of life sciences workers are 55 or older, and the training pipeline is not producing bio-literate graduates at the pace the sector adds jobs. The public foundations are under strain as well. The National Institutes of Health seeds the basic science behind most new medicines, and full funding of that engine has slipped down the list of national priorities. The Food and Drug Administration faces the same drift, since regulatory speed determines whether discoveries reach patients here
or somewhere else first. Both should be American advantages, and sustained commitment would make them so. None of this registers as a crisis in the moment, which is exactly what makes it dangerous. That erosion has been easy to miss because Washington has spent two decades debating medicine as a pricing question. A security frame asks something different: who controls a therapy once it exists? Whoever discovers the next generation of treatments gains substantial influence over where and how they are developed, how they are distributed, and,
ultimately, how quickly they reach patients. Seen through that lens, the dependencies now forming look familiar. If China restricted access to its trials, its manufactured goods, or its data collaborations, American access to the newest cures could narrow sharply. In any other strategic technology sector America competes in, an exposure of that kind would already be treated as a national security vulnerability. | | The advantage America holds | America is not starting this competition from behind. When America has mobilized science at scale before, it has done so by pairing government purpose with private industry, and that machinery still exists. University research, private
risk capital, and federal science link more productively here than under any centrally directed model, and together they still produce the majority of the world's new medicines. That is the first American advantage, and it remains the hardest for a competitor to replicate. The second advantage is structural. A century of trusted relationships has left the United States with capable partners, and Japan, South Korea, the European Union, and India each hold real capacity in chemistry, manufacturing, or clinical
infrastructure. Coordinated as a network with aligned standards and predictable procurement, those partners provide strategic depth no nation could create on its own and make supply chains far more difficult for any single government to disrupt. Lending and infrastructure deals cannot produce that kind of alignment. Domestic capacity is the other half of the answer, and the Department of War is investing in it through BioMADE and the Distributed Bioindustrial Manufacturing Program, both aimed at reducing logistical
vulnerability and producing critical materials on demand. Defense industrial policy has used this pattern before: government absorbs early risk in capabilities that markets are unlikely to finance on their own, while industry builds and operates the resulting infrastructure. The capability remains in commercial hands, where competition and investment continue to improve it, and distributed production extends the model into places that could never have supported a legacy plant. |
|
|
|
|
